271 related articles for article (PubMed ID: 20532510)
1. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH
Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510
[TBL] [Abstract][Full Text] [Related]
2. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer.
Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration.
Hellenthal NJ; Shariat SF; Margulis V; Karakiewicz PI; Roscigno M; Bolenz C; Remzi M; Weizer A; Zigeuner R; Bensalah K; Ng CK; Raman JD; Kikuchi E; Montorsi F; Oya M; Wood CG; Fernandez M; Evans CP; Koppie TM
J Urol; 2009 Sep; 182(3):900-6. PubMed ID: 19616245
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
Soga N; Arima K; Sugimura Y
Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome.
Yafi FA; Tanguay S; Rendon R; Jacobsen N; Fairey A; Izawa J; Kapoor A; Black P; Lacombe L; Chin J; So A; Lattouf JB; Bell D; Fradet Y; Saad F; Matsumoto E; Drachenberg D; Cagiannos I; Kassouf W
Urol Oncol; 2014 Jan; 32(1):31.e17-24. PubMed ID: 23428535
[TBL] [Abstract][Full Text] [Related]
6. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
7. Outcomes for patients with pT0 disease after radical nephroureterectomy for upper-tract urothelial carcinoma.
Raman JD; Ng CK; Shariat SF; Margulis V; Montorsi F; Karakiewicz P;
BJU Int; 2009 Jan; 103(1):3-4. PubMed ID: 18717670
[No Abstract] [Full Text] [Related]
8. The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.
Sun P; Xue C; Li LR; Shao C; An X; Thomas R; Yang W; Deng YF; Jiang WQ; Shi YX
Cancer Chemother Pharmacol; 2017 Jul; 80(1):37-44. PubMed ID: 28534209
[TBL] [Abstract][Full Text] [Related]
9. Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
Shirotake S; Kikuchi E; Tanaka N; Matsumoto K; Miyazaki Y; Kobayashi H; Ide H; Obata J; Hoshino K; Kaneko G; Hagiwara M; Kosaka T; Kanao K; Kodaira K; Hara S; Oyama M; Momma T; Miyajima A; Nakagawa K; Hasegawa S; Nakajima Y; Oya M
J Urol; 2015 Apr; 193(4):1122-8. PubMed ID: 25444957
[TBL] [Abstract][Full Text] [Related]
10. A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy.
Kitamura H; Igarashi M; Tanaka T; Shindo T; Masumori N; Tamakawa M; Kawaai Y; Tsukamoto T
Jpn J Clin Oncol; 2012 Dec; 42(12):1192-6. PubMed ID: 23077244
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.
Vassilakopoulou M; de la Motte Rouge T; Colin P; Ouzzane A; Khayat D; Dimopoulos MA; Papadimitriou CA; Bamias A; Pignot G; Nouhaud FX; Hurel S; Guy L; Bigot P; Roumiguié M; Rouprêt M;
Cancer; 2011 Dec; 117(24):5500-8. PubMed ID: 21638278
[TBL] [Abstract][Full Text] [Related]
12. [Clinical studies of chemotherapy for patients with a solitary kidney after nephroureterectomy for advanced upper urothelial transitional cell carcinoma].
Tsujimura A; Takayama H; Tsukikawa M; Imazu T; Sugao H; Takaha M
Hinyokika Kiyo; 1995 Mar; 41(3):183-9. PubMed ID: 7741070
[TBL] [Abstract][Full Text] [Related]
13. Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy.
Hoshino K; Kikuchi E; Tanaka N; Akita H; Ito Y; Miyajima A; Jinzaki M; Oya M
Jpn J Clin Oncol; 2012 Mar; 42(3):202-7. PubMed ID: 22246718
[TBL] [Abstract][Full Text] [Related]
14. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF;
BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study.
Nakagawa T; Komemushi Y; Kawai T; Otsuka M; Miyakawa J; Uemura Y; Kanatani A; Taguchi S; Naito A; Suzuki M; Nishimatsu H; Hirano Y; Tanaka Y; Matsumoto A; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
World J Urol; 2017 Oct; 35(10):1569-1575. PubMed ID: 28397000
[TBL] [Abstract][Full Text] [Related]
16. Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours.
Hollande C; Colin P; de La Motte Rouge T; Audenet F; Yates DR; Phé V; Ouzzane A; Droupy S; Ruffion A; de La Taille A; Guy L; Cussenot O; Rozet F; Xylinas E; Zerbib M; Spano JP; Khayat D; Bitker MO; Rouprêt M;
BJU Int; 2014 Apr; 113(4):574-80. PubMed ID: 23937547
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery.
Koda S; Mita K; Shigeta M; Usui T
Jpn J Clin Oncol; 2007 Apr; 37(4):296-301. PubMed ID: 17513309
[TBL] [Abstract][Full Text] [Related]
18. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study.
Seitz C; Gupta A; Shariat SF; Matsumoto K; Kassouf W; Walton TJ; Fritsche HM; Otto W; Tritschler S; Bastian PJ; Carballido J; Ficarra V; Karakiewicz PI; Artibani W; Mazzoleni G; Novara G
J Urol; 2010 Nov; 184(5):1895-900. PubMed ID: 20846680
[TBL] [Abstract][Full Text] [Related]
19. Case records of the Massachusetts General Hospital. Case 30-2009. A 77-year-old man with recurrent transitional-cell carcinoma of the ureter.
Kaufman DS; McDougal WS; Harisinghani MG; Wu CL
N Engl J Med; 2009 Sep; 361(13):1292-9. PubMed ID: 19776411
[No Abstract] [Full Text] [Related]
20. Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma.
Kim DS; Lee YH; Cho KS; Cho NH; Chung BH; Hong SJ
Urology; 2010 Feb; 75(2):328-32. PubMed ID: 20018349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
